(Q58614990)

English

A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer

scientific article published on 01 April 1995

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

cancer research

0 references

phase III clinical trial

1 reference

based on heuristic

inferred from title

randomized experiment

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Josep Tabernero Caturla

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

author name string

M C Alonso

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

B Ojeda

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

M Llanos

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

C Solà

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

M A Climent

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

M A Seguí

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

J J López

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

language of work or name

0 references

publication date

1 April 1995

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

34

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

15-24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

randomized experiment

0 references

A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Randomized trial comparing mitoxantrone with adriamycin in advanced breast cancer]

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of mitoxantrone and doxorubicin in breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitomycin C and vinblastine chemotherapy for advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dihydroxyanthracenedione: A Promising New Drug in the Treatment of Metastatic Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized comparison of cyclophosphamide-mitoxantrone-5-fluorouracil v cyclophosphamide-doxorubicin-5-fluorouracil in advanced breast cancer: preliminary observations

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer A Cancer and Leukemia Group B study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response of advanced breast carcinoma to the combination of the antimetabolite, Methotrexate, and the alkylating agent, thio-TEPA

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00666487

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58614990&oldid=2233279764"